321436-06-0

Basic information

• Product Name: BUTTPARK 120\07-73
• Synonyms: BUTTPARK 120\07-73;7-BROMO-2H-1,4-BENZOXAZIN-3(4H)-ONE;7-Bromo-2H-benzo[b][1,4]oxazin-3(4H)-one;-broMo-2H-benzo[b][1,4]oxazin-3(4H)-one;7-broMo-3,4-dihydro-2H-1,4-benzoxazin-3-one;BUTTPARK 120;7-BroMo-4H-benzo[1,4]oxazin-3-one;7-Bromo-4H-1,4-benzoxazin-3-one
• CAS NO: 321436-06-0
• Molecular Formula: C₈H₆BrNO₂
• Molecular Weight: 228.04
• Mol File: 321436-06-0.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 381.471°C at 760 mmHg
• Flash Point: 184.507°C
• Appearance: /
• Density: 1.676
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 11.76±0.20(Predicted)
• CAS DataBase Reference: BUTTPARK 120\07-73(CAS DataBase Reference)
• NIST Chemistry Reference: BUTTPARK 120\07-73(321436-06-0)
• EPA Substance Registry System: BUTTPARK 120\07-73(321436-06-0)

Safety Data

• Hazardous Substances Data: 321436-06-0(Hazardous Substances Data)

Usage

General Description

BUTTPARK 120\07-73 is a chemical mixture composed of butyl benzyl phthalate, diisononyl phthalate, and triethyl citrate. It is commonly used as a plasticizer in the production of flexible PVC products, such as vinyl flooring, cables, and artificial leather. As a plasticizer, this chemical blend helps to increase the flexibility, durability, and performance of PVC materials. However, it is important to handle and use BUTTPARK 120\07-73 with caution, as certain components in the mixture, such as butyl benzyl phthalate, have been associated with potential health risks and environmental concerns. Therefore, proper safety measures and regulations should be followed when handling and disposing of this chemical blend.

InChI:InChI=1/C8H6BrNO2/c9-5-1-2-6-7(3-5)12-4-8(11)10-6/h1-3H,4H2,(H,10,11)

Upstream product

• 5466-88-6 3,4-dihydro-3-oxo-2H-1,4-benzoxazine 
• 474806-63-8 2-((4-bromo-2-fluorophenyl)amino)-2-oxoethyl acetate 
• 367-24-8 4-bromo-2-fluoroaniline 
• 27684-84-0 5-bromo-2-nitrophenol 
• 1001004-08-5 N-(4-bromo-2-fluorophenyl)-2-hydroxyacetamide 
• 38191-34-3 2-amino-5-bromophenol 
• 79-04-9 chloroacetyl chloride 
• 26215-14-5 7-amino-2H-1,4-benzoxazin-3(4H)-one 

Downstream Products

• 1040236-26-7 4-benzyl-7-bromo-1,4-benzoxazin-3-one 

Relevant articles and documents

Synthesis, characterization and biological evaluation of 7-substituted- 4-((1-aryl-1H-1,2,3-triazol-4-yl) methyl)-2H-benzo[b][1,4]oxazin- 3(4H)-ones as anticancer agents

A series of novel 1,2,3-triazole-2H-benzo[b][1,4]oxazin-3(4H)-ones (4a–4k and 5a–5g) were designed, synthesized and screened for their anticancer activity against MCF-7 (breast) and HeLa (cervical) cell lines using [3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphen

2-AMINOPYRIMIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF

The disclosure provides an aminopyrimidine derivative for preventing and treating diseases related to IDH mutation, a preparation method and use thereof. Specifically, the disclosure provides a compound of Formula I, a stereoisomer, racemate thereof, or pharmaceutically acceptable salt thereof. The compound of the general Formula I has isocitrate dehydrogenase 1 (IDH1) inhibitory activity and can treat cancer induced by IDH1 mutation.

Discovery of new small molecule inhibitors targeting isocitrate dehydrogenase 1 (IDH1) with blood-brain barrier penetration

Isocitrate dehydrogenase 1 (IDH1), which catalyzes the conversion of isocitrate to α-ketoglutarate, is one of key enzymes in the tricarboxylic acid cycle (TCA). Hotspot mutation at Arg132 in IDH1 that alters the function of IDH1 by further converting the α-ketoglutarate(α-KG) to 2-hydroxyglutarate (2-HG) have been identified in a variety of cancers. Because the IDH1 mutations occur in a significant portion of gliomas and glioblastomas, it is important that IDH1 inhibitors have to be brain penetrant to treat IDH1-mutant brain tumors. Here we report the efforts to design and synthesize a novel serial of mutant IDH1 inhibitors with improved activity and the blood-brain barrier (BBB) penetration. We show that compound 5 exhibits good brain exposure and potent 2-HG inhibition in a HT1080-derived mouse xenograft model, which makes it a potential preclinical candidate to treat IDH1-mutant brain tumors.